BlackRock Fund Advisors’s Seres Therapeutics MCRB Stock Holding History

BlackRock Fund Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$10.9M	Buy	55,169 +5,463	+11%	+$1.19M	﹤0.01%	2524
2016 Q3	$12.2M	Buy	49,706 +3,332	+7%	+$1.17M	﹤0.01%	2343
2016 Q2	$26.9M	Buy	46,374 +10,548	+29%	+$6.19M	0.01%	1870
2016 Q1	$19M	Buy	35,826 +2,722	+8%	+$1.42M	﹤0.01%	2015
2015 Q4	$23.2M	Buy	33,104 +22,866	+223%	+$15M	0.01%	1943
2015 Q3	$6.07M	Buy	+10,238	New	+$8.35M	﹤0.01%	2682

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's MCRB Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Seres Therapeutics (MCRB) stake by 11% in Q4 2016, buying an estimated $1.19M and bringing the position to 55,169 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2524.

BlackRock Fund Advisors first reported a position in MCRB in Q3 2015 and has held it in 6 quarters since. The position peaked at $26.9M in Q2 2016. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

BlackRock Fund Advisors held 55,169 shares of Seres Therapeutics worth $10.9M as of Q4 2016.
BlackRock Fund Advisors bought 5,463 Seres Therapeutics shares in Q4 2016, an estimated $1.19M.
Seres Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2524 holding.
BlackRock Fund Advisors first reported a position in Seres Therapeutics in Q3 2015 and has held it in 6 quarters since.
BlackRock Fund Advisors's Seres Therapeutics position peaked at $26.9M in Q2 2016.
89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.